(2020 / 01 / 06) anesthesia three oligarchs "attack" injection big variety! Four class 1 new drugs have made great efforts in the 10 billion market; the share price of two phase III clinical failures of novan antiviral sb206 has plummeted by 74%; the logic and implementation path of medical policy in 2019 are reviewed; the domestic bio similar drugs that are expected to be approved in 2020 are expected to be approved Black swans are capricious 2019 is the year of policy implementation The old shareholders made additional investment again Take a quick look at the overall logic of health policy in 2019 Are you interested? Believe in the level of medical care in China Very interesting competitive landscape This is an issue that enterprises need to consider Hengrui is the first to break through.
This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only.
This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of
the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed
description of the concern or complaint, to
service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content
will be removed immediately.
